AI Article Synopsis
- The study aimed to understand patient preferences regarding pen injectors used in Assisted Reproduction Technology (ART) in France, focusing on treatment adherence.
- Using a discrete choice experiment with 155 women averaging 34 years old, researchers evaluated six attributes related to injector pens.
- Results indicated that patients highly valued features like dose confirmation, digital dose counters, multi-use capabilities, and the convenience of ready-to-use pens.
Article Abstract
Background: The preference of patients in the choice of pen injectors for Assisted Reproduction Technology (ART) is an important issue for treatment adherence. This study, based on discrete choice experiment (DCE), aimed to elicit patients' preferences of the characteristics of all pen injectors available in France.
Research Design And Methods: A DCE with 12 choice sets was developed to measure the preferences of 6 attributes: pre-injection steps, injection device, dose release, post-injection display, dose reduction method, and dose counter. A mixed logistic model was used to determine the preference ranks and calculate utility score.
Results: The study involved 155 women who had previous experience with the use of injector pens with an average age of 34.1 years. Statistically significant results showed that the most essential characteristics were dose confirmation ( < 0.0001), dose counter with digits ( < 0.0001), multi-use pen ( < 0.0001) and ready-to-use pens ( < 0.0001). Estimation of the utilities showed statistically significant difference in favor of Gonal-f®/Pergoveris® (reference modalities) versus other pens, and the largest difference was with Rekovelle® [95% CI:-1,37;-0.85], and Bemfola® [95% CI:-2.25;-1,52].
Conclusions: This study show that respondent preferred pen that are ready to use, can be used multiple times, have dose injection confirmation, and display the dose with digits.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/17425247.2024.2434030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Patient preferences on pen injectors for assisted reproductive technology: a discrete choice experiment in France.
Expert Opin Drug Deliv
December 2024
Antoine Béclère Hospital, Department of Reproductive Medicine and Fertility Preservation, Clamart, France.
Article Synopsis
- The study aimed to understand patient preferences regarding pen injectors used in Assisted Reproduction Technology (ART) in France, focusing on treatment adherence.
- Using a discrete choice experiment with 155 women averaging 34 years old, researchers evaluated six attributes related to injector pens.
- Results indicated that patients highly valued features like dose confirmation, digital dose counters, multi-use capabilities, and the convenience of ready-to-use pens.
Patients with Growth-Related Disorders and Caregivers Prefer the Somapacitan Device to the Somatrogon Device: Results from a Randomized Crossover Study Assessing Device Preference and Ease of Use Following Simulated Injections.
Med Devices (Auckl)
October 2024
Medical & Science, Devices & Digital Health, Novo Nordisk A/S, Søborg, Denmark.
Purpose: Adherence to growth hormone treatment is known to affect growth outcomes. Both device preference and ease of use have been shown to affect treatment adherence. In this study, we assessed device preference and ease of use with two long-acting growth hormones, somapacitan (Sogroya, Novo Nordisk A/S) and somatrogon (Ngenla, Pfizer).
View Article and Find Full Text PDFA Risk-Based Assessment for Determining the Pharmacokinetic Comparability Requirements of Biologic-Device Combination Products Administered by Subcutaneous Injection.
AAPS J
September 2024
Regulatory Affairs, Chemistry, Manufacturing and Controls, Novo Nordisk A/S, Søborg, Denmark.
The development of new large molecule drug therapies along with the innovation of biologic-device combination products such as prefilled syringes, autoinjectors and pen injectors have significantly impacted the treatment of new diseases and has improved the process of administering parenteral medicines. To support the regulatory approval of a new biologic-device combination products or subsequent chemistry, manufacturing and control changes impacting a combination product, sponsor companies must thoroughly assess the potential impact to product quality, safety and efficacy. In this report, a risk-based process to determine the potential impact to product quality, safety, and efficacy as well as corresponding regulatory actions supporting a chemistry, manufacturing and control change is presented.
View Article and Find Full Text PDFTrends in the market for drug delivery devices categorized as combination drugs and medical devices and regulatory challenges for autoinjectors in Japan.
Front Med Technol
August 2024
Department of Regulatory Science, Graduate School of Pharmaceutical Science, Meiji Pharmaceutical University, Tokyo, Japan.
Background: Although a variety of drug delivery devices have been launched in recent years, few studies have comprehensively investigated the market trends of combination drugs and medical devices approved or certified in Japan and the regulatory challenges related to their approval. Among the drug delivery devices, autoinjectors are more convenient than traditional prefilled syringes and are designed with safety features to prevent needlestick accidents, allowing self-injection by patients. Therefore, autoinjectors have been incorporated into the treatment of various diseases and have shown significant growth among drug delivery devices.
View Article and Find Full Text PDFThe Concizumab Pen-Injector is Easy to Use and Preferred by Hemophilia Patients and Caregivers: A Usability Study Assessing Pen-Injector Handling and Preference.
Patient Prefer Adherence
August 2024
Medical & Science Innovation, Novo Nordisk A/S, Søborg, Denmark.
Introduction: Concizumab is a once-daily prophylactic treatment developed for patients with hemophilia A or B (HA/HB) with or without inhibitors. It is the first treatment for hemophilia patients to be delivered subcutaneously using a pre-filled, multi-dose pen-injector with a 4 mm, 32 G needle.
Aim: To investigate patient and caregiver handling and preference for the concizumab pen-injector compared with current injection systems used to treat hemophilia.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!